Format

Send to

Choose Destination
Med Decis Making. 2015 Feb;35(2):145-7. doi: 10.1177/0272989X14563082. Epub 2014 Dec 10.

The need for transparency and efficiency in reimbursement decisions relating to drugs for rare diseases.

Author information

1
Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada (DC)
2
Division of Hematology/Oncology, Sunnybrook Health Sciences Centre, Odette Cancer Center, University of Toronto, Toronto, ON, Canada (MCC)
3
Division of Infectious Diseases, Department of Medicine, Kingston General Hospital and Queen's University, Kingston, ON, Canada (GAE)
PMID:
25505026
DOI:
10.1177/0272989X14563082
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center